JVS-vascular science最新文献

{"title":"Aortoiliac fenestrated stent demonstrates superior flow dynamics to kissing iliac stents in a large animal","authors":"Maxwell C. Braasch MD, MPH,&nbsp;Ryan Wahidi MD,&nbsp;Sophia R. Pyeatte MD,&nbsp;Santiago Elizondo-Benedetto MD,&nbsp;Mohamed Zaghloul MD,&nbsp;Hanxun Jin MS,&nbsp;John Cashin BS,&nbsp;DeVaughn Rucker MS,&nbsp;Shahab Hafezi MD,&nbsp;Batool Arif MS,&nbsp;Guy M. Genin PhD,&nbsp;Mohamed A. Zayed MD, PhD, MBA","doi":"10.1016/j.jvssci.2026.100439","DOIUrl":"10.1016/j.jvssci.2026.100439","url":null,"abstract":"<div><h3>Objective</h3><div>Current endovascular treatment of aortoiliac occlusive disease with kissing iliac stents has suboptimal long-term patency and durability secondary to pathologic flow fields. The aortoiliac fenestrated (AIFEN) stent was previously introduced to provide an anatomically preserving endovascular therapy that may improve flow dynamics compared with kissing iliac stents. The aim of this study was to compare flow dynamics between the AIFEN stent and conventional kissing iliac stents in vivo in an adult porcine model.</div></div><div><h3>Methods</h3><div>AIFEN stents were manufactured via benchtop modification of standard balloon-expandable covered stents. Three adult Yorkshire pigs underwent endovascular AIFEN implantation in the distal aorta with bilateral iliac stents (group 1), whereas three pigs received conventional kissing iliac stents (group 2). Over 4 weeks of survival, patency was assessed using weekly femoral ultrasound. Pre-explant computed tomography angiography with computational flow modeling was used to evaluate arterial flow dynamics, including vorticity and flow rate.</div></div><div><h3>Results</h3><div>All pigs in both groups survived the 4-week study period without complications. Fluoroscopy at implantation and terminal procedures confirmed patent stents in all animals. Serial ultrasound demonstrated patent bilateral femoral artery outflow throughout the study. Computed tomography angiography-based flow dynamic analysis revealed that group 1 had significantly reduced iliac artery vorticity (<em>P</em> = .02) and higher flow rates (<em>P</em> = .004) compared with group 2.</div></div><div><h3>Conclusions</h3><div>The anatomically designed AIFEN stent demonstrated superior flow dynamics compared with kissing iliac stents in a porcine model. These findings support further development of anatomically preserving balloon-expandable stent designs to improve endovascular treatment of aortoiliac occlusive disease.</div></div><div><h3>Clinical relevance</h3><div>Endovascular treatment of aortoiliac occlusive disease commonly relies on kissing iliac stents; yet, this configuration alters native aortoiliac geometry and can generate disturbed flow patterns that contribute to thrombosis. In this large-animal study, an anatomically preserving aortoiliac fenestrated stent configuration demonstrated significantly improved flow dynamics compared with conventional kissing iliac stents, including reduced vorticity and increased flow rates. By maintaining more physiologic aortoiliac architecture, the aortoiliac fenestrated approach may mitigate adverse hemodynamic conditions associated with current endovascular strategies. These findings support further development of anatomically guided stent designs for the infrarenal aortic bifurcation that are aimed at improving durability and outcomes in patients with aortoiliac occlusive disease.</div></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100439"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148995279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to clinical translation of small-diameter tissue-engineered vascular grafts in peripheral reconstruction","authors":"Miguel Castro e Silva MD,&nbsp;Leonor Baldaia MD,&nbsp;Luís Orelhas MD,&nbsp;Jorge Costa MD,&nbsp;Paula Dias MD,&nbsp;Beatriz Tavares MD,&nbsp;Eduardo Silva MD,&nbsp;Celso Nunes MD,&nbsp;Manuel Fonseca MD","doi":"10.1016/j.jvssci.2026.100435","DOIUrl":"10.1016/j.jvssci.2026.100435","url":null,"abstract":"<div><h3>Objective</h3><div>To provide a comprehensive review of small-diameter (&lt;6 mm) tissue-engineered vascular grafts for peripheral vascular applications, examining mechanisms of graft failure, emerging biomaterial and fabrication strategies, and key considerations for clinical translation.</div></div><div><h3>Methods</h3><div>A comprehensive literature review was performed using PubMed, Scopus, and Web of Science through January 2026. Studies were selected on the basis of relevance to peripheral vascular surgery, with emphasis on preclinical and clinical outcomes, biomaterial performance, fabrication approaches, and translational considerations, prioritizing recent studies while including seminal work.</div></div><div><h3>Results</h3><div>Despite over four decades of research, small-diameter synthetic grafts continue to demonstrate poor patency in infrainguinal bypass, with expanded polytetrafluoroethylene and Dacron achieving 25% to 50% patency at 5 years compared with 60% to 80% for autologous saphenous vein in below-the-knee applications. Up to 20% of patients experience graft thrombosis within 6 months, with early failure associated with increased amputation rates. Graft failure is driven by acute thrombosis, intimal hyperplasia related to compliance mismatch and chronic inflammation, and incomplete endothelialization. Emerging strategies include multilayered scaffold architectures, hybrid biomaterials incorporating extracellular matrix components and bioactive molecules, advanced manufacturing techniques such as melt electrowriting, and immunomodulatory approaches promoting constructive remodeling. Recent preclinical studies report high patency rates approaching 100%, with complete endothelialization and minimal intimal hyperplasia in animal models. However, translation remains limited by inadequate study design, with median graft lengths of ∼5 cm and follow-up periods of ∼56 days, which do not reflect clinical scenarios where grafts often exceed 30 cm.</div></div><div><h3>Conclusions</h3><div>Clinically viable small-diameter tissue-engineered vascular grafts for peripheral vascular reconstruction will require integrated optimization of hemocompatibility, endothelialization, biomechanical properties, and inflammatory response. Advances in biomaterials, manufacturing technologies, and mechanistic understanding suggest that grafts meeting clinical benchmarks may be achievable, but progress will depend on rigorous preclinical evaluation using clinically relevant models and end points.</div></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100435"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148843641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effects of hemoglobin vesicles on intestinal ischemia-reperfusion injury in a rat model of thoracic aortic occlusion","authors":"Keisuke Tsuruta PhD, MD ,&nbsp;Hidetada Fukushima PhD, MD ,&nbsp;Hiromi Sakai PhD","doi":"10.1016/j.jvssci.2026.100418","DOIUrl":"10.1016/j.jvssci.2026.100418","url":null,"abstract":"<div><div>Intestinal ischemia-reperfusion (I/R) injury is a major complication of aortic occlusion during resuscitative thoracotomy or resuscitative endovascular balloon occlusion of the aorta. We investigated whether targeted intra-arterial delivery of hemoglobin vesicles (HbVs) attenuates intestinal I/R injury in a rat thoracic aortic cross-clamping model. Male Wistar rats underwent 60 minutes of thoracic aortic occlusion followed by 60 minutes of reperfusion. Animals received intra-arterial HbV (1.25 mL/kg every 10 minutes; n = 5) or saline (n = 5) via the femoral artery; sham animals (n = 3) underwent instrumentation only. Compared with saline controls, HbV-treated rats demonstrated higher postreperfusion systolic blood pressure (56 ± 4 mm Hg vs 34 ± 8 mm Hg; <em>P</em> = .002) and lower plasma lactate levels (2.7 ± 0.4 mmol/L vs 7.5 ± 0.4 mmol/L; <em>P</em> &lt; .001). Intestinal injury was significantly attenuated in the HbV group, with lower Chiu scores (median 2.0 vs 4.0; <em>P</em> = .018), reduced terminal deoxynucleotidyl transferase dUTP nick end labeling-positive area fraction (<em>P</em> = .003), and decreased inducible nitric oxide synthase-positive area fraction (<em>P</em> = .006). Targeted intra-arterial HbV administration significantly reduced early intestinal I/R injury in this exploratory proof-of-concept model and may represent a promising adjunctive oxygen-carrying strategy to protect distal organs during prolonged aortic occlusion.</div></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100418"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147991614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What does matter in tide—rising tide or ebbing tide—in aortic branch design?","authors":"Nabil Chakfe MD, PhD ,&nbsp;Anne Lejay MD, PhD","doi":"10.1016/j.jvssci.2026.100420","DOIUrl":"10.1016/j.jvssci.2026.100420","url":null,"abstract":"","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100420"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147740113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombogenicity of stent graft materials as a potential contributing factor to limb graft occlusions","authors":"Job van Helvoirt MSc,&nbsp;Hannah Jeffers MSc,&nbsp;Michael Wolf MSc,&nbsp;Hugo ten Cate PhD, MD,&nbsp;Carlijn Bouten PhD,&nbsp;Simon Overeem PhD,&nbsp;Erik Groot Jebbink PhD, MD,&nbsp;Michel Reijnen PhD, MD","doi":"10.1016/j.jvssci.2026.100436","DOIUrl":"10.1016/j.jvssci.2026.100436","url":null,"abstract":"<div><h3>Objective</h3><div>Limb graft occlusions (LGOs) remain a significant complication after endovascular aneurysm repair. Several clinical risk factors have been recognized, but these do not fully account for the consistently observed different LGO rates among major commercial stent graft systems. This paper investigates the thrombogenicity of stent graft materials as a potential factor for thrombus formation and therefore LGO.</div></div><div><h3>Methods</h3><div>The thrombogenicity of the graft materials from three commercially available stent grafts (Zenith Alpha, Endurant, and Excluder) was evaluated in vitro using whole blood from four human donors for 1 hour in a dynamic setup. Samples were examined qualitatively with scanning electron microscopy, and the blood was further evaluated quantitatively via enzyme-linked immunosorbent assays for key indicators of thrombogenesis: normalized platelet count in the blood as measure of platelets in the clot, thrombin-antithrombin complex (TAT), β-thromboglobulin (βTG), and the soluble complement membrane attack complex (sC5b9).</div></div><div><h3>Results</h3><div>Qualitative analysis revealed voluminous blot clot formation on Zenith Alpha stent grafts, some blood components on Endurant fabric, and minimal thrombotic factors on Excluder fabric. Material from the Zenith Alpha exhibited the lowest normalized platelet count in the blood (<em>P</em> &lt; .0001) and significantly higher TAT (<em>P</em> &lt; .001) and βTG values compared with Excluder (<em>P</em> = .002), indicating quantitatively the highest thrombogenicity among the evaluated stent graft materials. The Endurant fabric was significantly less thrombogenic compared with Zenith Alpha based on normalized platelet count (<em>P</em> &lt; .001) and TAT values (<em>P</em> &lt; .001). The Excluder graft material had the highest normalized platelet count (<em>P</em> &lt; .0001) and lowest values of TAT (<em>P</em> &lt; .0001) and βTG (<em>P</em> &lt; .018), indicating that it is significantly less thrombogenic compared with the other two fabrics. No clear trend was found for sC5b9 between the stent graft materials.</div></div><div><h3>Conclusions</h3><div>The materials used in three commercial stent graft systems have significantly different in vitro thrombogenic properties and thrombus formation on the fabrics.</div></div><div><h3>Clinical relevance</h3><div>The found variations of material thrombogenicity between the Zenith Alpha, Endurant, and Excluder stent grafts appear to align with their reported clinical limb graft occlusion rates of these devices. By considering material thrombogenicity and thus thrombus formation, clinicians gain a deeper understanding of device-specific risks that may guide stent graft selection and postprocedural management. In general, these findings exemplify the potential relationship between implantable material properties and clinical complications, which remains insufficiently explored.</div></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100436"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149051130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sutureless repair of inferior vena cava injury using an elastomeric sealant in a mouse model with histopathological analysis of vascular healing","authors":"Yoshinori Nakahara MD,&nbsp;Shin-ichiro Ohno PhD,&nbsp;Tomohiro Iwakura MD, PhD,&nbsp;Koji Fujita BS,&nbsp;Shouichirou Mineo BS,&nbsp;Masahiko Kuroda MD, PhD","doi":"10.1016/j.jvssci.2026.100438","DOIUrl":"10.1016/j.jvssci.2026.100438","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To evaluate the feasibility of sutureless repair for inferior vena cava (IVC) injury using an elastomeric sealant (Hydrofit; Sanyo Chemical Industries) and to characterize the histopathological pathway of vascular healing in a mouse model.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Nineteen male C57BL/6 mice underwent laparotomy under general anesthesia. A longitudinal incision exceeding 1 mm was made in the infrarenal IVC, and hemostasis was achieved using Hydrofit-applied sheets with 2 minutes of compression. The primary end point was immediate hemostatic success rate with exact 95% confidence intervals (CIs). Surviving mice were distributed across the three time points (n = 6, 6, and 6 at days 5, 10, and 30, respectively) by random allocation; one mouse at day 30 was excluded from histopathological scoring owing to inability to reliably identify the incision site. CD31 immunostaining was performed to assess endothelial coverage at the repair site. Findings were scored using a semiquantitative system modified from the Histopathological Evaluation of Acute and Long-Term Healing Scores for Advancing Wound Healing Science-Acute scale, with comparisons among time points using the Kruskal-Wallis test.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Immediate hemostasis was achieved in all 19 mice (100%; 95% CI, 82.4%-100%). One mouse died on postoperative day 2; anesthesia-related complications were the most likely cause, but because necropsy was not performed, procedure-related hemorrhage could not be definitively excluded, an unavoidable limitation of the primary and survival outcome estimates. The overall survival rate was 94.7% (18/19; 95% CIs, 74.0%-99.9%). No intra-abdominal adhesions were observed. Histopathological scoring demonstrated significant progression through wound healing phases (&lt;em&gt;P&lt;/em&gt; = .001), with total scores increasing from 4.7 ± 1.2 at day 5 (inflammatory phase) to 7.7 ± 0.8 at day 10 (proliferative phase) and 11.4 ± 1.8 at day 30 (early maturation phase). CD31 (platelet endothelial cell adhesion molecule-1) immunostaining demonstrated CD31-positive cells at the luminal surface at all three time points; a morphologically confirmed endothelial monolayer on hematoxylin and eosin and Elastica van Gieson staining was identified at days 10 and 30, whereas elastic lamina regeneration was not observed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Sutureless repair using an elastomeric sealant is feasible for IVC injury in this mouse model, achieving reliable hemostasis. Although the initial wound healing response follows a physiological inflammatory-proliferative-maturation sequence culminating in endothelial coverage established by day 10, the late process is accompanied by material-driven fibrous encapsulation and intimal hyperplasia at the repair site.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Clinical relevance&lt;/h3&gt;&lt;div&gt;Venous injuries are challenging to repair due to the fragile vessel wall. This study provides histopathological evidence t","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100438"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148958296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum levels of neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) in patients with asymptomatic and symptomatic carotid artery stenosis","authors":"Robin Jansen MD ,&nbsp;Markus U. Wagenhäuser MD ,&nbsp;Tristan Kölsche MD ,&nbsp;Cleopatra Papasimos ,&nbsp;Pascal Benkert PhD ,&nbsp;Jens Kuhle MD ,&nbsp;Marc Pawlitzki MD ,&nbsp;Lars Masanneck MD ,&nbsp;Stefanie Schreiber MD ,&nbsp;Julian Caspers MD ,&nbsp;Tobias Ruck MD ,&nbsp;Ramona Hagler ,&nbsp;Malin Stassen ,&nbsp;Daniel Weiss MD ,&nbsp;Philipp Arndt ,&nbsp;Marc Dörner ,&nbsp;Joscha Mulorz MD ,&nbsp;Sven G. Meuth MD, PhD ,&nbsp;Hubert Schelzig MD ,&nbsp;John-Ih Lee MD ,&nbsp;Michael Gliem MD","doi":"10.1016/j.jvssci.2026.100408","DOIUrl":"10.1016/j.jvssci.2026.100408","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;The treatment of carotid artery stenosis (CAS) for stroke prevention is a matter of debate due to conflicting data, missing recent data, and advances in medical treatment options but also in interventional techniques and surgery. Therefore, the establishment of an easily available marker for brain damage might be a key tool in this patient group to guide treatment.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A retrospective cross-sectional study was conducted leveraging a vascular surgery biobank of 95 patients aged 60 to 80 years. Serum neurofilament light chain (sNfL) and serum glial fibrillary acid protein (sGFAP) were evaluated using highly sensitive electrochemiluminescence immunoassays and z-scores. Discriminatory performance was assessed to differentiate between 19 symptomatic and 76 asymptomatic patients with CAS and their correlation with the degree of stenosis according to ultrasound-based North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;SNfL levels were markedly elevated in symptomatic compared with asymptomatic patients (median 17.4 vs 3.8 pg/mL; &lt;em&gt;P&lt;/em&gt; &lt; .001). sNfL robustly discriminated between these patients (area under the curve = 0.83; 95% confidence interval, 0.72-0.94), as did the NfL z-score (area under the curve = 0.83; 95% confidence interval, 0.71-0.95). Interestingly, within the asymptomatic cohort, sNfL levels demonstrated a significant, positive correlation with the degree of stenosis (Spearman's ρ = 0.24; &lt;em&gt;P&lt;/em&gt; = .036). Serum levels of SGFAP were also associated with symptomatic status, albeit with a &lt;em&gt;P&lt;/em&gt;-value &gt;.05 (0.1 vs 0.1 pg/mL; (&lt;em&gt;P&lt;/em&gt; = .057).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;The study provides evidence of increased sNfL in symptomatic vs asymptomatic CAS and, of note, of ongoing neuronal or glial damage in some patients with clinically asymptomatic CAS, with a positive correlation between sNfL and the degree of CAS. sNfL is a promising and already accessible blood biomarker that may guide therapeutic decisions in this patient population. The role of sGFAP remains elusive and must be evaluated in larger studies.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Clinical Relevance&lt;/h3&gt;&lt;div&gt;The CREST-2 trial has recently highlighted the high efficacy of intensive medical management in asymptomatic carotid artery stenosis (CAS), making the selection of patients for revascularization increasingly complex. Our study addresses this challenge by evaluating serum neurofilament light chain (sNfL) and serum glial fibrillary acid protein (sGFAP) as an objective biomarker for neuronal injury. Using individualized z-scores, we demonstrate that sNfL effectively differentiates symptomatic status (area under the curve = 0.828) and significantly correlates with the degree of stenosis in asymptomatic cohorts. These results suggest that sNfL can detect subclinical “silent” damage, providing a valuable biological tool to pinpoint high-risk patie","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100408"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bones of contention: Hematopoietic marrow within the artery wall","authors":"Linda L. Demer MD, PhD ,&nbsp;Yin Tintut PhD","doi":"10.1016/j.jvssci.2026.100412","DOIUrl":"10.1016/j.jvssci.2026.100412","url":null,"abstract":"","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100412"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147384834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter regarding “Reduced Fistula Patency in Female Mice”","authors":"Fatih Kizilyel MD","doi":"10.1016/j.jvssci.2025.100406","DOIUrl":"10.1016/j.jvssci.2025.100406","url":null,"abstract":"","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100406"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between vascular smooth muscle cells isolated from descending thoracic and abdominal aortas of mice in cell function, phenotype features, and gene expression","authors":"Keisuke Kamada MD ,&nbsp;Hong Niu PhD ,&nbsp;Fan Zhang PhD ,&nbsp;Gale L. Tang MD","doi":"10.1016/j.jvssci.2026.100411","DOIUrl":"10.1016/j.jvssci.2026.100411","url":null,"abstract":"<div><h3>Background</h3><div>Vascular smooth muscle cells (VSMCs) are the primary component of the medial layer of the vessel wall, where they maintain structural integrity and regulate vascular tone. Their dysfunction contributes to vascular diseases such as aortic aneurysms and atherosclerosis. Although VSMCs isolated from thoracic and abdominal aortic regions are widely used in experimental studies, their functional differences have not been systematically compared.</div></div><div><h3>Methods</h3><div>In this study, we examined functional and phenotypic differences between VSMCs isolated from the descending thoracic (Th-SMCs) and abdominal aortas of male C57BL/6J mice under controlled in vitro conditions.</div></div><div><h3>Results</h3><div>Both cell types maintained high α-smooth muscle actin expression across passages, supporting smooth muscle lineage identity. Functionally, Th-SMCs demonstrated significantly greater migratory and proliferative capacities compared with abdominal SMCs. Under sublethal oxidative stress, Th-SMCs exhibited higher relative viability, accompanied by higher basal expression of antioxidant-related transcripts, including <em>Nrf2</em>, <em>Catalase</em>, and <em>Sod1</em>.</div></div><div><h3>Conclusions</h3><div>These findings highlight intrinsic differences between region-specific VSMCs and underscore the importance of considering anatomical origin for in vitro models. Incorporating region-specific VSMCs may enhance experimental relevance and contribute to a better understanding of the mechanisms underlying regional vascular diseases.</div></div><div><h3>Clinical Relevance</h3><div>Vascular smooth muscle cells (VSMCs) play a key role in the development of vascular diseases. This study demonstrates that VSMCs isolated from the descending thoracic and abdominal aortic regions exhibit distinct functional behaviors under in vitro conditions. These region-specific differences highlight the importance of carefully selecting and reporting the anatomical origin of VSMCs in experimental studies, which may improve the physiological relevance and interpretability of vascular research models.</div></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100411"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147384833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}